Non-selective kinase inhibitors
AssigneePulmokine, Inc.
InventorLawrence S Zisman
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.
Claims20
A method of reducing phosphorylation of an extracellular signal-regulated kinase (ERK), the method comprising administering to a subject a therapeutically-effective amount of a compound of the formula:
- or a pharmaceutically-acceptable salt thereof.
A method of reducing phosphorylation of a serine/threonine kinase, the method comprising administering to a subject a therapeutically-effective amount of a compound of the formula:
- or a pharmaceutically-acceptable salt thereof, wherein the serine/threonine kinase is AKT.
Dependencies are inferred from the claim text.